Saquinavir mesylate - Generic Drug Details

What are the generic drug sources for saquinavir mesylate and what is the scope of freedom to operate?

Saquinavir mesylate is the generic ingredient in one branded drug marketed by Hoffmann La Roche and Hoffmann-la Roche, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for saquinavir mesylate

US Patents:	0
Tradenames:	1
Applicants:	2
NDAs:	2
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	8
What excipients (inactive ingredients) are in saquinavir mesylate?	saquinavir mesylate excipients list
DailyMed Link:	saquinavir mesylate at DailyMed

Recent Clinical Trials for saquinavir mesylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	N/A
AIDS Clinical Trials Group	N/A
Abbott	Phase 2

See all saquinavir mesylate clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for saquinavir mesylate

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for saquinavir mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann-la Roche	INVIRASE	saquinavir mesylate	TABLET;ORAL	021785-001	Dec 17, 2004		DISCN	Yes	No
Hoffmann La Roche	INVIRASE	saquinavir mesylate	CAPSULE;ORAL	020628-001	Dec 6, 1995		DISCN	Yes	No

Saquinavir Mesylate Market Dynamics, Patent Expiration, FDA Status, and Financial Trajectory

Last updated: September 6, 2026

Saquinavir mesylate is a mature HIV-1 protease inhibitor with limited current commercial relevance. Hoffmann-La Roche launched Invirase in 1995 and Fortovase in 1997, but the products lost strategic importance after newer protease inhibitors and integrase inhibitors entered the HIV market. The principal patent estate expired years ago, no meaningful biosimilar issue exists, and generic entry risk is primarily commercial rather than legal.

Saquinavir remains relevant as a historical antiretroviral and as a case study in rapid product obsolescence within HIV treatment. Its current value is constrained by twice-daily dosing, mandatory ritonavir boosting, extensive drug interactions, cardiac safety warnings, and competition from once-daily integrase inhibitor regimens.

What is saquinavir mesylate and how is it used?

Saquinavir mesylate is the mesylate salt of saquinavir, an HIV-1 protease inhibitor. It prevents cleavage of viral polyproteins required to produce mature infectious HIV particles.

The FDA-approved product is administered with ritonavir and other antiretroviral agents. Ritonavir inhibits CYP3A-mediated metabolism and increases saquinavir exposure. Saquinavir should not be used as an unboosted treatment regimen.

Attribute	Saquinavir mesylate
Therapeutic class	HIV-1 protease inhibitor
Original developer	Hoffmann-La Roche
Brand names	Invirase; Fortovase
FDA approval	Invirase, 1995; Fortovase, 1997
Booster requirement	Ritonavir
Historical dosage forms	Hard gelatin capsules, tablets, soft gelatin capsules
Typical use	Combination antiretroviral therapy
Current market position	Mature, low-priority HIV product
Biosimilar relevance	None; saquinavir is a small molecule
Main competitors	Darunavir, atazanavir, dolutegravir, bictegravir, cabotegravir and other modern antiretrovirals

The FDA label identifies saquinavir/ritonavir treatment as requiring attention to QT and PR interval prolongation, drug interactions, hepatic impairment, and contraindicated co-medications.[1]

When did saquinavir mesylate lose exclusivity?

Saquinavir’s primary composition-of-matter and product-protection period ended well before the current decade. The historical U.S. patent portfolio included patents covering the hydroxyethylamine protease-inhibitor structure, saquinavir, salt forms, and pharmaceutical formulations. Representative historical U.S. patents include U.S. Patent Nos. 5,196,438 and 5,413,999.[2][3]

Protection category	Historical position
Active pharmaceutical ingredient	Expired
Saquinavir mesylate salt	Expired or no longer commercially blocking
Hard-capsule formulation	Expired
Soft-gel formulation	Expired
Ritonavir-boosted treatment method	No current blocking exclusivity identified
U.S. regulatory exclusivity	Expired
Current patent-based entry barrier	Low

The exact expiration date for an individual historical patent depended on filing date, patent-term rules, patent-term adjustment and any applicable pediatric extension. Those variables did not preserve a commercially material monopoly into the present market.

Saquinavir is therefore an off-patent small molecule. The commercial question is not whether a company can lawfully develop a generic, but whether the expected demand justifies formulation, bioequivalence, manufacturing and regulatory costs.

What was the FDA regulatory history of Invirase and Fortovase?

The FDA approved Invirase in December 1995 as the first marketed saquinavir product. Fortovase, a soft gelatin formulation intended to improve oral bioavailability, followed in 1997.[4]

Invirase

Invirase was initially supplied as 200 mg hard gelatin capsules and later as 500 mg tablets. The product required combination use and later became primarily associated with ritonavir boosting.

Fortovase

Fortovase used a soft gelatin formulation designed to improve absorption relative to the original hard-capsule product. Roche discontinued Fortovase in major markets after utilization declined and the product became commercially unattractive.[5]

Regulatory status

The regulatory history includes:

• FDA approval of saquinavir for combination HIV therapy.
• Label revisions addressing ritonavir boosting, drug interactions and cardiac electrophysiology.
• Product discontinuation or limited marketing activity in certain jurisdictions.
• Continued historical presence in FDA and drug-label databases despite declining commercial availability.

FDA Drugs@FDA and the Orange Book distinguish between an approved product and a product currently marketed. A listing does not establish that a product has active commercial supply.[6][7]

What is the Orange Book status of saquinavir mesylate?

Saquinavir mesylate has no meaningful current Orange Book exclusivity position. Historical brand products and associated patents may remain visible in FDA records even when the underlying products are discontinued or no longer commercially significant.

The Orange Book is relevant for determining listed patents and regulatory certifications, but it does not create a new monopoly after listed patents expire. For saquinavir, the practical conclusion is:

1. The historical patents are expired.
2. Regulatory exclusivity has ended.
3. No current branded exclusivity supports premium pricing.
4. A generic applicant would face ordinary ANDA requirements rather than a material patent blockade.

Because saquinavir is a small molecule, the relevant regulatory pathway is an abbreviated new drug application, not a biosimilar application under the Public Health Service Act.

Which companies are challenging saquinavir mesylate patents?

No major current Paragraph IV campaign has materially affected the saquinavir market. The commercial patent-challenge period occurred years ago, when the product had greater clinical use and the relevant patents were approaching expiration.

Paragraph IV risk

A modern generic applicant would normally evaluate:

• Expired compound and salt patents.
• Any remaining formulation or method-of-use listings.
• Bioequivalence requirements for the selected dosage form.
• The need to demonstrate product performance with ritonavir.
• Manufacturing and supply economics.

The absence of prominent current Paragraph IV litigation reflects the product’s age and limited market opportunity. It should not be interpreted as evidence that saquinavir has a strong patent estate.

Litigation status

No material active U.S. patent litigation involving saquinavir mesylate is broadly associated with the current market. Historical disputes, regulatory proceedings or product-supply issues do not create a present patent barrier unless tied to an unexpired, enforceable claim.

What formulations are protected by saquinavir patents?

Saquinavir’s historical intellectual-property coverage included several formulation approaches.

Formulation	Commercial purpose	Current IP position
Hard gelatin capsule	Original oral dosage form	Historical protection expired
500 mg tablet	Higher-strength oral dosage form	Historical protection expired or nonblocking
Soft gelatin capsule	Improved bioavailability	Historical protection expired
Ritonavir-boosted regimen	Increased systemic exposure	No meaningful current exclusivity identified
Manufacturing and salt processes	Improved production and product handling	Any historical barriers are no longer commercially material

The formulation problem was clinically important. Saquinavir had poor oral bioavailability, which drove development of Fortovase and later reliance on ritonavir boosting. Formulation complexity did not translate into durable commercial protection because the relevant products became obsolete before a new lifecycle strategy could create sustained demand.

How strong is the saquinavir mesylate patent estate?

The current patent estate is weak from a market-exclusivity perspective.

Strength assessment

Factor	Assessment	Rationale
Composition-of-matter protection	Very weak	Historical patents expired
Salt-form protection	Very weak	No current blocking position identified
Formulation protection	Very weak	Legacy dosage-form patents expired
Method-of-use protection	Weak	Broad HIV treatment use is mature and heavily disclosed
Manufacturing protection	Low to moderate	Process know-how may matter operationally but is not a branded monopoly
Regulatory exclusivity	None material	Product is long past initial approval
Litigation leverage	Low	Limited commercial value reduces incentive for enforcement
Generic launch barrier	Low legally; moderate operationally	Demand and formulation economics are the main constraints

The most defensible residual advantage would be manufacturing know-how, validated supply chains and regulatory files. Those are operational assets, not durable patent exclusivity.

How does saquinavir compare with newer HIV drugs?

Saquinavir has lost market share because modern HIV regimens offer better dosing convenience, tolerability, interaction profiles and treatment durability.

Drug or class	Dosing profile	Commercial advantage over saquinavir
Saquinavir/ritonavir	Typically twice daily with booster	Established historical efficacy but high interaction burden
Darunavir/ritonavir	Once or twice daily depending on regimen	Higher resistance barrier and broader clinical use
Atazanavir/ritonavir	Once daily	Lower pill burden in selected patients
Dolutegravir	Once daily	Strong efficacy, high resistance barrier, no pharmacokinetic booster
Bictegravir combinations	Once daily, fixed-dose combination	Convenience and broad first-line use
Cabotegravir long-acting	Injectable maintenance	Reduces daily oral dosing burden

U.S. and international HIV treatment guidelines have moved toward integrase strand transfer inhibitor-based regimens for most treatment-naive patients.[8][9] This shift reduced the clinical role of older protease inhibitors, including saquinavir.

Saquinavir also carries disadvantages that are difficult to overcome through price competition:

• Ritonavir boosting is required.
• CYP3A-mediated interactions complicate co-medication management.
• QT and PR interval concerns restrict use in some patients.
• The formulation history is complex.
• It is not a preferred modern first-line option.
• There is no compelling convenience advantage.

What is the market size and financial trajectory for saquinavir?

Standalone saquinavir revenue is not generally disclosed in current public financial reporting. Roche reports pharmaceutical performance at broader product or franchise levels, and saquinavir is not a material separately reported growth product.

The financial trajectory follows four phases:

Period	Market phase	Financial direction
1995-1997	Launch and formulation expansion	Rapid growth from first-in-class protease-inhibitor demand
Late 1990s-2000s	Combination-therapy adoption	Significant clinical use, with competition emerging
2010s	Mature decline	Falling use as newer protease and integrase inhibitors displaced it
2020s	Residual or limited availability	Low strategic value and limited standalone revenue

Saquinavir’s revenue decline was driven by therapeutic substitution rather than a single patent cliff. The product first faced competition from other protease inhibitors with better potency, dosing or resistance profiles. It later faced replacement by integrase inhibitor regimens, particularly fixed-dose once-daily combinations.

Revenue exposure

Roche’s current financial exposure to saquinavir is expected to be immaterial relative to its oncology, immunology, ophthalmology and other major pharmaceutical businesses. No current public disclosure indicates that saquinavir contributes a material share of group revenue.

For a generic manufacturer, the addressable opportunity would be limited by:

• Small and shrinking patient demand.
• Competition from established generic antiretrovirals.
• Low willingness of payers to preserve an obsolete regimen.
• Manufacturing requirements for a low-volume product.
• Limited clinical preference among prescribers.
• Potential difficulty securing commercial distribution.

What generic entry risks exist for saquinavir mesylate?

Generic entry risk is high in legal terms but moderate or low in commercial terms.

Legal entry scenario

A generic manufacturer could pursue an ANDA for a relevant dosage form after confirming that no unexpired Orange Book-listed patent blocks approval. The principal legal challenges would involve bioequivalence, product labeling, formulation selection and any residual listed patents.

Commercial launch scenarios

Scenario	Likely outcome
Single generic entrant	Limited supply, low-volume niche
Multiple generic entrants	Rapid price erosion and weak margins
Authorized or legacy supply only	Continued residual use without broad market expansion
New formulation entrant	Low probability because clinical demand is limited
Repositioning in treatment guidelines	Unlikely without new clinical evidence

A generic launch would not restore the branded market. It would mainly preserve access for patients already receiving the drug or for settings where treatment alternatives are unavailable.

What manufacturing and IP barriers remain?

Manufacturing barriers are more relevant than patent barriers.

Saquinavir mesylate manufacturers must manage:

• Active pharmaceutical ingredient sourcing.
• Salt formation and control of solid-state properties.
• Dosage-form dissolution and bioavailability.
• Batch consistency for an older formulation.
• Stability and packaging requirements.
• Supply-chain economics for low-volume demand.
• Regulatory support for discontinued or rarely used dosage forms.

The soft gelatin formulation presents greater manufacturing complexity than a conventional tablet or capsule. A tablet or capsule generic may be operationally simpler, but its commercial opportunity is correspondingly narrow.

No biosimilar risk exists because saquinavir is not a biologic. The competitive threat comes from generic small-molecule supply and therapeutic substitution by other antiretroviral classes.

What licensing deals affect saquinavir mesylate?

Saquinavir was developed and commercialized by Roche, and its principal commercial history is linked to Roche’s Invirase and Fortovase products. No major current licensing transaction appears to drive the product’s market position.

The absence of active licensing activity is consistent with the product’s low commercial value. Any current rights would likely concern legacy regulatory files, regional distribution or supply arrangements rather than strategic global commercialization.

Key Takeaways

• Saquinavir mesylate is an off-patent, mature HIV protease inhibitor.
• Invirase was FDA-approved in 1995; Fortovase followed in 1997.
• Historical compound, salt and formulation patents expired years ago.
• No material current Orange Book exclusivity or Paragraph IV litigation drives the market.
• Saquinavir has no biosimilar exposure because it is a small molecule.
• Market decline resulted from therapeutic substitution by newer protease inhibitors and integrase inhibitors.
• Ritonavir boosting, drug interactions, cardiac warnings and twice-daily dosing limit use.
• Current standalone revenue is not materially disclosed and is expected to be negligible relative to Roche’s overall business.
• Generic entry is legally feasible, but low demand and weak margins constrain commercial interest.
• Residual value lies in legacy supply, access continuity and manufacturing know-how rather than patent protection.

FAQs

Is saquinavir mesylate still FDA approved?

Historical Invirase approvals remain documented in FDA records, but FDA approval status and active commercial marketing are separate questions. Product availability has become limited and jurisdiction-dependent.

Is saquinavir mesylate a generic drug?

The active ingredient is off patent, making generic development legally possible. The availability of a marketed generic depends on dosage form, supplier economics and regulatory filings.

Does saquinavir mesylate have biosimilar competition?

No. Saquinavir is a chemically synthesized small molecule, so competition occurs through generic-drug pathways rather than biosimilar regulation.

Why did Fortovase leave the HIV market?

Fortovase became commercially unattractive as newer antiretroviral regimens offered better dosing, tolerability, interaction profiles and clinical positioning.

Can saquinavir mesylate regain market share?

A broad recovery is unlikely without a major change in treatment guidelines, new clinical evidence or a differentiated delivery technology. Current HIV treatment trends favor integrase inhibitors and simplified fixed-dose regimens.

References

1. U.S. Food and Drug Administration. (2013). Invirase (saquinavir mesylate) prescribing information.
2. U.S. Patent No. 5,196,438. (1993). Hydroxyethylamine compounds useful as HIV protease inhibitors. United States Patent and Trademark Office.
3. U.S. Patent No. 5,413,999. (1995). HIV protease inhibitors and pharmaceutical compositions. United States Patent and Trademark Office.
4. U.S. Food and Drug Administration. (1995). FDA approves Invirase for HIV infection.
5. Roche. (2006). Annual report.
6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
7. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
8. National Institutes of Health. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.
9. World Health Organization. (2021). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring.